Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
fda
life sciences
national blog main
national top stories
new york blog main
3
×
roche
3
×
san francisco blog main
biotech
boulder/denver blog main
boulder/denver top stories
cancer
companion diagnostic
detroit blog main
detroit top stories
foundation medicine
national
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
advaxis
aimmune therapeutics
alder biopharmaceuticals
alexander hardy
andrew oxtoby
babies
blueprint medicines
boston
breakup
bridge bio pharma
What
medicine
3
×
big
acquire
agreed
approved
billion
bio
bosley's
bosley’s
bridge
broad
bucks
cancer
cas
ceo
confidence
crime
crispr
deeper
departure
didn’t
dna
drug
editas
exit
fda
fingerprint
foundation
gain
genentech
genetic
going
guiding
katrine
matter
momentum
morning
moves
nd
new
Language
Current search:
roche
×
medicine
×
" new york blog main "
×
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine